

# Russell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.6	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	10	7.2	139.5	(66.8-256.5)	Female	0	0.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.4	nc	(nc-nc)
Male	6	1.8	332.1	(121.3-722.9)	<b><u>Ovary</u></b>				
Female	3	1.6	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	5	5.4	92.3	(29.8-215.5)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.4	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.4	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.5	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	23	22.1	104.1	(66.0-156.3)
Female	0	0.2	nc	(nc-nc)	Female	25	22.7	110.0	(71.2-162.4)
<b><u>Lung and Bronchus</u></b>									
Male	3	3.0	nc	(nc-nc)					
Female	3	3.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Rutland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	6.9	nc	(nc-nc)	Male	6	5.0	120.6	(44.1-262.6)
Female	2	2.3	nc	(nc-nc)	Female	1	3.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	6	4.5	134.1	(49.0-291.9)
Female	38	32.7	116.2	(82.2-159.5)	Female	2	3.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.7	nc	(nc-nc)
Male	11	8.2	134.7	(67.1-241.0)	<b><u>Ovary</u></b>				
Female	9	7.0	128.8	(58.8-244.4)	Female	2	2.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	5	2.4	207.0	(66.7-483.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	24	26.2	91.6	(58.7-136.3)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.8	nc	(nc-nc)
Male	2	5.0	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.4	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	6.6	90.5	(33.1-197.1)
Male	7	3.2	220.5	(88.3-454.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.0	nc	(nc-nc)	Female	6	7.6	79.4	(29.0-172.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	2.9	nc	(nc-nc)	Male	103	101.9	101.1	(82.5-122.6)
Female	1	0.9	nc	(nc-nc)	Female	92	102.0	90.2	(72.7-110.6)
<b><u>Lung and Bronchus</u></b>									
Male	18	12.5	143.6	(85.1-227.0)					
Female	7	13.0	53.7	(21.5-110.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Salem

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	39	35.0	111.4	(79.2-152.3)	Male	33	23.4	141.1	(97.1-198.2)
Female	13	16.1	80.6	(42.9-137.9)	Female	26	23.0	113.2	(73.9-165.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	7.4	134.3	(64.3-247.0)	Male	4	7.3	nc	(nc-nc)
Female	3	7.6	nc	(nc-nc)	Female	14	7.5	185.8	(101.5-311.8)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	1.3	nc	(nc-nc)	Male	21	20.9	100.5	(62.2-153.6)
Female	164	179.7	91.3	(77.8-106.4)	Female	23	22.3	103.1	(65.4-154.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	6.0	100.4	(36.7-218.6)	Male	24	17.6	136.2	(87.2-202.6)
<b><u>Colon / Rectum</u></b>					Female	17	9.9	171.9	(100.1-275.2)
Male	35	38.2	91.7	(63.9-127.5)	<b><u>Ovary</u></b>				
Female	35	46.1	75.9	(52.8-105.5)	Female	12	15.7	76.3	(39.4-133.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	12	9.0	133.7	(69.0-233.6)	Male	11	13.2	83.4	(41.6-149.2)
Female	5	3.1	159.8	(51.5-373.0)	Female	15	16.7	89.6	(50.1-147.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	3.3	nc	(nc-nc)	Male	145	108.0	134.3	(113.3-158.0)
Female	8	3.3	240.5	(103.6-473.9)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	13	8.4	154.9	(82.4-265.0)
Male	24	21.3	112.6	(72.1-167.6)	Female	3	6.5	nc	(nc-nc)
Female	13	14.5	89.9	(47.8-153.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	7	6.4	109.8	(44.0-226.2)
Male	6	5.3	113.2	(41.3-246.4)	<b><u>Thyroid</u></b>				
Female	5	2.0	250.7	(80.8-585.0)	Male	10	10.2	97.7	(46.8-179.6)
<b><u>Leukemia</u></b>					Female	43	34.8	123.4	(89.3-166.2)
Male	13	15.0	86.8	(46.2-148.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	13	13.4	97.4	(51.8-166.5)	Female	44	41.0	107.4	(78.0-144.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	17	12.8	132.3	(77.0-211.8)	Male	549	462.5	118.7	(109.0-129.1)
Female	2	5.5	nc	(nc-nc)	Female	614	607.6	101.1	(93.2-109.4)
<b><u>Lung and Bronchus</u></b>									
Male	77	61.7	124.7	(98.4-155.9)					
Female	89	84.0	106.0	(85.1-130.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Salisbury

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	10.6	113.6	(58.6-198.4)	Male	11	6.8	162.8	(81.2-291.3)
Female	4	3.6	nc	(nc-nc)	Female	4	5.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	2.0	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	6	6.0	99.9	(36.5-217.4)
Female	41	43.5	94.2	(67.6-127.8)	Female	6	5.0	119.8	(43.7-260.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.4	nc	(nc-nc)	Male	13	5.2	249.4	(132.7-426.5)
<b><u>Colon / Rectum</u></b>					Female	4	2.3	nc	(nc-nc)
Male	13	11.0	118.5	(63.0-202.6)	<b><u>Ovary</u></b>				
Female	14	10.1	138.0	(75.4-231.6)	Female	7	3.6	192.9	(77.3-397.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.8	nc	(nc-nc)	Male	5	4.0	125.7	(40.5-293.3)
Female	1	0.7	nc	(nc-nc)	Female	6	3.7	161.1	(58.8-350.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	30	35.2	85.3	(57.5-121.8)
Female	2	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	2.5	nc	(nc-nc)
Male	5	6.3	78.8	(25.4-184.0)	Female	1	1.4	nc	(nc-nc)
Female	4	3.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.2	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	7.8	116.1	(53.0-220.3)
Male	3	4.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.9	nc	(nc-nc)	Female	12	10.2	117.3	(60.6-205.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	3.9	nc	(nc-nc)	Male	141	138.5	101.8	(85.7-120.1)
Female	2	1.2	nc	(nc-nc)	Female	163	140.6	115.9	(98.8-135.2)
<b><u>Lung and Bronchus</u></b>									
Male	25	19.1	131.2	(84.9-193.7)					
Female	28	19.4	144.0	(95.6-208.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sandisfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	2.2	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	1	4.5	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	2.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	1.0	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	5.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.5	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.8	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	0.3	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	7	23.0	30.4	(12.2-62.6)
Female	0	0.1	nc	(nc-nc)	Female	8	14.3	55.8	(24.0-110.0)
<b><u>Lung and Bronchus</u></b>									
Male	1	3.5	nc	(nc-nc)					
Female	3	2.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sandwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	34	25.8	131.5	(91.1-183.8)	Male	19	16.3	116.2	(69.9-181.5)
Female	9	9.4	95.4	(43.5-181.1)	Female	16	12.8	125.3	(71.6-203.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	4.6	195.3	(89.1-370.7)	Male	8	5.3	149.6	(64.4-294.7)
Female	7	4.2	168.2	(67.4-346.5)	Female	2	4.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	21	14.5	145.2	(89.9-222.0)
Female	122	106.0	115.0	(95.5-137.4)	Female	15	12.9	116.3	(65.0-191.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.2	nc	(nc-nc)	Male	11	12.3	89.4	(44.6-160.0)
<b><u>Colon / Rectum</u></b>					Female	7	5.7	122.0	(48.9-251.4)
Male	22	26.6	82.7	(51.8-125.3)	<b><u>Ovary</u></b>				
Female	22	26.2	83.8	(52.5-126.9)	Female	10	9.1	110.5	(52.9-203.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	6.6	75.5	(24.3-176.2)	Male	15	9.6	155.9	(87.2-257.2)
Female	5	1.9	267.0	(86.0-623.0)	Female	9	9.7	92.6	(42.2-175.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.6	nc	(nc-nc)	Male	83	80.5	103.1	(82.1-127.8)
Female	2	1.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	6.0	99.3	(36.3-216.1)
Male	10	14.8	67.4	(32.3-124.0)	Female	4	3.7	nc	(nc-nc)
Female	7	8.5	82.6	(33.1-170.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	2.6	nc	(nc-nc)
Male	4	3.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.2	nc	(nc-nc)	Male	1	6.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	18.0	55.4	(26.5-102.0)
Male	9	10.1	89.3	(40.8-169.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	7.4	80.6	(29.4-175.5)	Female	28	24.7	113.2	(75.2-163.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	9.3	75.0	(30.1-154.6)	Male	332	328.9	100.9	(90.4-112.4)
Female	1	3.2	nc	(nc-nc)	Female	356	351.7	101.2	(91.0-112.3)
<b><u>Lung and Bronchus</u></b>									
Male	33	45.7	72.2	(49.7-101.4)					
Female	47	50.3	93.4	(68.7-124.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Saugus

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	53	33.5	158.1	(118.4-206.8)	Male	15	21.2	70.6	(39.5-116.5)
Female	18	13.9	129.4	(76.6-204.5)	Female	20	18.1	110.4	(67.4-170.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	5.9	117.9	(47.2-242.9)	Male	5	6.9	73.0	(23.5-170.3)
Female	7	5.8	121.0	(48.5-249.4)	Female	5	6.4	78.0	(25.1-182.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	1.2	nc	(nc-nc)	Male	36	18.8	191.6	(134.1-265.2)
Female	145	147.6	98.2	(82.9-115.6)	Female	24	18.7	128.6	(82.4-191.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	4.5	nc	(nc-nc)	Male	20	15.4	130.0	(79.3-200.7)
<b><u>Colon / Rectum</u></b>					Female	8	8.2	98.1	(42.3-193.4)
Male	48	34.6	138.7	(102.3-183.9)	<b><u>Ovary</u></b>				
Female	27	38.9	69.5	(45.8-101.1)	Female	5	12.8	39.1	(12.6-91.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	16	8.3	192.8	(110.1-313.1)	Male	18	12.3	145.8	(86.3-230.4)
Female	6	2.7	222.1	(81.1-483.3)	Female	13	14.5	89.5	(47.6-153.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	2.2	nc	(nc-nc)	Male	79	97.2	81.3	(64.3-101.3)
Female	4	2.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	7.8	nc	(nc-nc)
Male	24	18.8	127.9	(81.9-190.3)	Female	2	5.4	nc	(nc-nc)
Female	8	12.0	66.8	(28.8-131.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	10	4.0	253.0	(121.1-465.4)
Male	6	4.9	122.8	(44.8-267.3)	<b><u>Thyroid</u></b>				
Female	0	1.7	nc	(nc-nc)	Male	8	8.1	98.7	(42.5-194.5)
<b><u>Leukemia</u></b>					Female	22	24.7	88.9	(55.7-134.6)
Male	17	13.0	130.5	(76.0-209.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	10.7	nc	(nc-nc)	Female	37	34.1	108.6	(76.4-149.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	21	11.6	181.5	(112.3-277.4)	Male	506	417.9	121.1	(110.8-132.1)
Female	5	4.6	109.9	(35.4-256.4)	Female	489	500.6	97.7	(89.2-106.7)
<b><u>Lung and Bronchus</u></b>									
Male	67	58.7	114.2	(88.5-145.0)					
Female	89	72.9	122.1	(98.1-150.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Savoy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	2	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	3	3.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	0.7	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	3.6	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.3	nc	(nc-nc)
Male	2	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	0.6	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	7	15.0	46.8	(18.7-96.4)
Female	0	0.1	nc	(nc-nc)	Female	11	10.0	110.3	(55.0-197.4)
<b><u>Lung and Bronchus</u></b>									
Male	2	2.1	nc	(nc-nc)					
Female	1	1.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Scituate

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	23	23.2	99.0	(62.8-148.6)	Male	46	14.6	315.9	(231.3-421.4)
Female	12	8.9	134.9	(69.6-235.7)	Female	27	12.0	225.1	(148.3-327.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	4.1	196.1	(84.4-386.5)	Male	7	4.7	149.0	(59.7-307.1)
Female	2	3.8	nc	(nc-nc)	Female	2	4.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	7	12.8	54.7	(21.9-112.7)
Female	95	98.7	96.3	(77.9-117.7)	Female	9	12.0	74.8	(34.1-141.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	3.1	nc	(nc-nc)	Male	9	10.6	84.8	(38.7-161.0)
<b><u>Colon / Rectum</u></b>					Female	5	5.4	93.4	(30.1-218.0)
Male	20	23.7	84.2	(51.4-130.1)	<b><u>Ovary</u></b>				
Female	20	25.8	77.5	(47.3-119.7)	Female	9	8.4	106.8	(48.7-202.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	11	5.7	191.4	(95.4-342.4)	Male	7	8.5	82.5	(33.1-170.0)
Female	4	1.7	nc	(nc-nc)	Female	1	9.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	1.4	nc	(nc-nc)	Male	59	67.3	87.7	(66.7-113.1)
Female	0	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	5.4	93.2	(30.0-217.6)
Male	11	12.9	85.1	(42.4-152.2)	Female	6	3.6	165.6	(60.5-360.5)
Female	7	7.8	89.3	(35.8-183.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.4	nc	(nc-nc)
Male	3	3.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	2	5.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	16	17.2	93.3	(53.3-151.5)
Male	9	9.1	99.3	(45.3-188.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	7.1	70.0	(22.5-163.3)	Female	23	21.9	104.9	(66.5-157.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	9	8.0	112.7	(51.4-214.0)	Male	301	287.4	104.7	(93.2-117.3)
Female	4	3.0	nc	(nc-nc)	Female	316	329.1	96.0	(85.7-107.2)
<b><u>Lung and Bronchus</u></b>									
Male	33	40.3	81.8	(56.3-114.9)					
Female	48	45.8	104.8	(77.3-138.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Seekonk

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	18.0	61.0	(30.4-109.2)	Male	7	11.6	60.2	(24.1-124.1)
Female	1	6.1	nc	(nc-nc)	Female	9	8.8	101.8	(46.5-193.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.3	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
Female	1	2.9	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	14	10.1	138.3	(75.6-232.1)
Female	40	74.0	54.0	(38.6-73.6)	Female	4	8.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.4	nc	(nc-nc)	Male	4	8.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	4	3.9	nc	(nc-nc)
Male	14	18.5	75.6	(41.3-126.9)	<b><u>Ovary</u></b>				
Female	9	17.2	52.3	(23.9-99.4)	Female	6	6.3	95.9	(35.0-208.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	4.7	nc	(nc-nc)	Male	5	6.7	74.2	(23.9-173.1)
Female	0	1.2	nc	(nc-nc)	Female	8	6.2	128.0	(55.1-252.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	35	58.4	59.9	(41.7-83.3)
Female	0	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	4.3	nc	(nc-nc)
Male	4	10.7	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
Female	0	5.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	2.1	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	0	4.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	13.5	74.2	(35.5-136.5)
Male	7	7.0	99.8	(40.0-205.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	4.9	nc	(nc-nc)	Female	9	17.4	51.7	(23.6-98.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	6.5	nc	(nc-nc)	Male	153	234.3	65.3	(55.4-76.5)
Female	0	2.1	nc	(nc-nc)	Female	144	239.6	60.1	(50.7-70.8)
<b><u>Lung and Bronchus</u></b>									
Male	23	33.1	69.5	(44.0-104.3)					
Female	26	33.1	78.5	(51.2-115.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sharon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	20.5	53.7	(26.8-96.2)	Male	13	13.5	96.1	(51.1-164.4)
Female	7	6.0	116.4	(46.6-239.8)	Female	17	9.6	176.2	(102.6-282.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	4.0	125.9	(40.6-293.9)	Male	3	4.4	nc	(nc-nc)
Female	0	3.1	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	12	11.9	100.7	(52.0-176.0)
Female	88	81.0	108.6	(87.1-133.8)	Female	7	9.0	78.2	(31.3-161.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.8	nc	(nc-nc)	Male	8	10.7	74.6	(32.1-147.0)
<b><u>Colon / Rectum</u></b>					Female	1	4.1	nc	(nc-nc)
Male	11	22.4	49.2	(24.5-88.1)	<b><u>Ovary</u></b>				
Female	12	18.3	65.5	(33.8-114.5)	Female	5	6.7	74.3	(23.9-173.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	5.5	nc	(nc-nc)	Male	10	7.9	127.4	(61.0-234.2)
Female	2	1.2	nc	(nc-nc)	Female	9	6.3	143.1	(65.3-271.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	57	68.1	83.7	(63.4-108.4)
Female	1	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	5.0	121.0	(44.2-263.4)
Male	7	12.9	54.4	(21.8-112.1)	Female	4	2.5	nc	(nc-nc)
Female	7	6.1	115.3	(46.2-237.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	2.4	nc	(nc-nc)
Male	1	3.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	8	5.6	142.5	(61.3-280.7)
<b><u>Leukemia</u></b>					Female	24	15.9	150.9	(96.7-224.6)
Male	8	8.3	96.4	(41.5-189.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	5.2	nc	(nc-nc)	Female	22	18.3	119.9	(75.1-181.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	7.7	64.6	(20.8-150.7)	Male	213	273.3	77.9	(67.8-89.1)
Female	3	2.1	nc	(nc-nc)	Female	275	254.6	108.0	(95.6-121.6)
<b><u>Lung and Bronchus</u></b>									
Male	20	36.7	54.5	(33.3-84.1)					
Female	44	32.5	135.5	(98.4-181.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sheffield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	5.8	86.0	(27.7-200.8)	Male	2	3.4	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
Female	15	17.7	84.8	(47.4-139.9)	Female	1	2.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	6	2.4	246.0	(89.8-535.5)
<b><u>Colon / Rectum</u></b>					Female	3	1.0	nc	(nc-nc)
Male	5	5.7	87.7	(28.3-204.7)	<b><u>Ovary</u></b>				
Female	5	4.4	113.3	(36.5-264.3)	Female	0	1.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	16	16.7	95.9	(54.8-155.8)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.3	nc	(nc-nc)
Male	3	3.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.4	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	2.8	nc	(nc-nc)
Male	0	2.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.2	nc	(nc-nc)	Female	5	4.3	117.4	(37.8-274.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	54	69.4	77.9	(58.5-101.6)
Female	0	0.6	nc	(nc-nc)	Female	56	59.1	94.7	(71.5-123.0)
<b><u>Lung and Bronchus</u></b>									
Male	6	10.2	59.1	(21.6-128.6)					
Female	13	8.6	150.7	(80.2-257.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Shelburne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	3.0	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	0.5	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	11	11.6	95.0	(47.3-169.9)	Female	2	1.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.6	nc	(nc-nc)
Male	3	3.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	2.9	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	10	9.9	100.8	(48.2-185.3)
Female	1	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.7	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.9	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.8	nc	(nc-nc)	Female	5	2.8	176.3	(56.8-411.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	35	38.9	90.0	(62.7-125.2)
Female	0	0.4	nc	(nc-nc)	Female	38	38.9	97.6	(69.1-134.0)
<b><u>Lung and Bronchus</u></b>									
Male	2	5.5	nc	(nc-nc)					
Female	4	5.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sherborn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	6.0	201.0	(103.7-351.1)	Male	6	3.7	163.4	(59.7-355.7)
Female	3	1.7	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
Female	19	20.6	92.2	(55.5-144.1)	Female	5	2.4	210.9	(68.0-492.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.1	nc	(nc-nc)
Male	9	6.1	147.0	(67.1-279.1)	<b><u>Ovary</u></b>				
Female	3	5.0	nc	(nc-nc)	Female	5	1.8	283.5	(91.4-661.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	1.5	nc	(nc-nc)	Male	5	2.2	230.3	(74.2-537.5)
Female	1	0.3	nc	(nc-nc)	Female	4	1.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	9	17.3	51.9	(23.7-98.5)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.4	nc	(nc-nc)
Male	2	3.3	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.5	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	3.7	nc	(nc-nc)
Male	2	2.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.4	nc	(nc-nc)	Female	3	4.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.0	nc	(nc-nc)	Male	62	73.1	84.8	(65.0-108.7)
Female	0	0.6	nc	(nc-nc)	Female	55	66.6	82.6	(62.2-107.5)
<b><u>Lung and Bronchus</u></b>									
Male	6	10.3	58.3	(21.3-126.9)					
Female	4	9.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Shirley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	7.1	196.9	(107.5-330.3)	Male	4	5.3	nc	(nc-nc)
Female	7	2.3	303.2	(121.5-624.7)	Female	1	3.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	9	4.7	192.0	(87.6-364.5)
Female	27	28.2	95.7	(63.0-139.2)	Female	3	3.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	1.5	nc	(nc-nc)
Male	11	8.6	127.7	(63.7-228.5)	<b><u>Ovary</u></b>				
Female	8	6.6	121.8	(52.5-240.1)	Female	3	2.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	2.0	249.7	(80.5-582.8)	Male	1	2.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	26	24.7	105.2	(68.7-154.1)
Female	1	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.8	nc	(nc-nc)
Male	6	5.1	117.5	(42.9-255.7)	Female	0	0.9	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.9	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	5.2	95.5	(30.8-222.9)
Male	4	3.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.8	nc	(nc-nc)	Female	12	6.5	183.8	(94.9-321.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	3.0	197.2	(72.0-429.2)	Male	115	104.0	110.6	(91.3-132.7)
Female	0	0.8	nc	(nc-nc)	Female	98	91.2	107.5	(87.2-131.0)
<b><u>Lung and Bronchus</u></b>									
Male	13	13.1	99.2	(52.8-169.7)					
Female	10	12.7	78.9	(37.8-145.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Shrewsbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	44	36.9	119.2	(86.6-160.0)	Male	19	23.9	79.5	(47.8-124.2)
Female	12	13.0	92.4	(47.7-161.4)	Female	21	19.0	110.8	(68.6-169.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	7.2	nc	(nc-nc)	Male	9	7.6	118.0	(53.9-224.1)
Female	2	6.3	nc	(nc-nc)	Female	7	6.0	116.1	(46.5-239.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	19	21.3	89.3	(53.7-139.4)
Female	175	152.8	114.5	(98.2-132.8)	Female	13	18.2	71.4	(38.0-122.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	7	5.4	130.2	(52.2-268.4)	Male	16	17.6	90.7	(51.8-147.4)
<b><u>Colon / Rectum</u></b>					Female	5	8.0	62.3	(20.1-145.5)
Male	42	39.5	106.4	(76.7-143.9)	<b><u>Ovary</u></b>				
Female	30	38.0	78.9	(53.2-112.6)	Female	13	12.9	101.1	(53.8-172.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	9.3	64.8	(23.7-141.0)	Male	11	13.6	80.6	(40.2-144.3)
Female	5	2.5	197.5	(63.6-460.9)	Female	11	13.5	81.7	(40.7-146.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.8	nc	(nc-nc)	Male	113	108.2	104.5	(86.1-125.6)
Female	2	2.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	8.7	57.3	(18.5-133.8)
Male	29	21.5	134.7	(90.2-193.5)	Female	5	5.3	93.6	(30.2-218.4)
Female	8	12.0	66.7	(28.7-131.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	5.4	nc	(nc-nc)
Male	5	5.4	93.3	(30.1-217.8)	<b><u>Thyroid</u></b>				
Female	0	1.6	nc	(nc-nc)	Male	15	10.0	149.7	(83.7-247.0)
<b><u>Leukemia</u></b>					Female	27	30.0	90.0	(59.3-130.9)
Male	19	15.1	125.9	(75.8-196.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	13	10.8	120.2	(64.0-205.6)	Female	29	33.1	87.7	(58.7-126.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	17	12.9	132.3	(77.0-211.8)	Male	479	469.9	101.9	(93.0-111.5)
Female	4	4.3	nc	(nc-nc)	Female	501	503.0	99.6	(91.1-108.7)
<b><u>Lung and Bronchus</u></b>									
Male	55	63.7	86.4	(65.0-112.4)					
Female	65	68.6	94.8	(73.2-120.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Shutesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	7	9.0	77.8	(31.2-160.4)	Female	1	1.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.5	nc	(nc-nc)
Male	0	2.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	1.9	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	3	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	7.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.5	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	1.7	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.5	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	11	26.7	41.2	(20.6-73.8)
Female	0	0.3	nc	(nc-nc)	Female	22	27.8	79.2	(49.6-119.9)
<b><u>Lung and Bronchus</u></b>									
Male	0	3.4	nc	(nc-nc)					
Female	2	3.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Somerset

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	36	28.3	127.2	(89.1-176.1)	Male	12	16.9	71.1	(36.7-124.2)
Female	11	9.5	116.0	(57.8-207.5)	Female	8	11.7	68.3	(29.4-134.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	4.6	130.7	(47.7-284.5)	Male	1	5.5	nc	(nc-nc)
Female	4	3.7	nc	(nc-nc)	Female	6	4.3	141.2	(51.5-307.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	15	14.9	100.7	(56.3-166.0)
Female	79	94.3	83.7	(66.3-104.4)	Female	18	12.3	146.0	(86.5-230.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.9	nc	(nc-nc)	Male	10	11.6	85.9	(41.1-157.9)
<b><u>Colon / Rectum</u></b>					Female	4	5.3	nc	(nc-nc)
Male	27	27.5	98.1	(64.7-142.8)	<b><u>Ovary</u></b>				
Female	30	26.2	114.7	(77.4-163.8)	Female	9	8.2	109.7	(50.1-208.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	6.7	120.1	(51.7-236.7)	Male	12	10.0	120.0	(61.9-209.6)
Female	1	1.8	nc	(nc-nc)	Female	12	9.9	121.3	(62.6-211.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	1.6	nc	(nc-nc)	Male	72	77.5	93.0	(72.7-117.1)
Female	0	1.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	11	6.3	173.9	(86.7-311.1)
Male	12	14.4	83.1	(42.9-145.2)	Female	6	3.7	163.1	(59.6-355.1)
Female	5	7.8	64.0	(20.6-149.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	2.7	186.1	(60.0-434.4)
Male	5	3.8	131.9	(42.5-307.8)	<b><u>Thyroid</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	6	5.8	104.1	(38.0-226.6)
<b><u>Leukemia</u></b>					Female	22	15.5	141.8	(88.9-214.8)
Male	11	10.6	103.9	(51.8-185.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	7.1	126.3	(57.6-239.8)	Female	22	21.2	103.7	(65.0-157.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	8.9	67.3	(24.6-146.5)	Male	334	334.3	99.9	(89.5-111.2)
Female	1	3.0	nc	(nc-nc)	Female	321	327.2	98.1	(87.7-109.4)
<b><u>Lung and Bronchus</u></b>									
Male	48	48.4	99.2	(73.1-131.5)					
Female	46	49.1	93.6	(68.5-124.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Somerville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	33	50.5	65.4	(45.0-91.8)	Male	29	34.5	84.1	(56.3-120.7)
Female	17	19.8	85.8	(49.9-137.4)	Female	26	31.2	83.4	(54.5-122.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	12.5	72.1	(32.9-137.0)	Male	8	10.5	76.5	(32.9-150.8)
Female	14	10.8	129.3	(70.6-216.9)	Female	10	9.2	108.8	(52.1-200.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	36	31.7	113.6	(79.5-157.2)
Female	195	222.1	87.8	(75.9-101.0)	Female	26	28.3	91.8	(59.9-134.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	12	8.3	144.7	(74.7-252.7)	Male	21	24.7	85.0	(52.6-130.0)
<b><u>Colon / Rectum</u></b>					Female	14	12.4	113.2	(61.8-189.9)
Male	52	54.7	95.1	(71.0-124.7)	<b><u>Ovary</u></b>				
Female	45	57.1	78.9	(57.5-105.5)	Female	23	20.0	115.0	(72.9-172.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	11	12.7	86.7	(43.2-155.1)	Male	16	18.7	85.6	(48.9-139.0)
Female	2	3.8	nc	(nc-nc)	Female	24	20.5	116.9	(74.9-173.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	8	7.7	104.4	(45.0-205.8)	Male	137	148.6	92.2	(77.4-109.0)
Female	5	6.7	74.3	(23.9-173.4)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	15	12.0	124.8	(69.8-205.9)
Male	30	30.3	99.2	(66.9-141.6)	Female	13	8.1	160.6	(85.4-274.6)
Female	21	18.1	116.3	(71.9-177.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	14	16.4	85.2	(46.5-142.9)
Male	6	7.4	80.8	(29.5-175.9)	<b><u>Thyroid</u></b>				
Female	4	2.4	nc	(nc-nc)	Male	20	17.2	116.2	(70.9-179.4)
<b><u>Leukemia</u></b>					Female	43	53.1	81.0	(58.6-109.1)
Male	20	23.4	85.6	(52.3-132.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	17	17.8	95.4	(55.6-152.8)	Female	56	50.1	111.8	(84.5-145.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	22	17.9	122.7	(76.8-185.7)	Male	648	676.0	95.9	(88.6-103.5)
Female	12	6.7	179.2	(92.5-313.1)	Female	751	771.6	97.3	(90.5-104.5)
<b><u>Lung and Bronchus</u></b>									
Male	117	87.2	134.1	(110.9-160.7)					
Female	105	103.6	101.4	(82.9-122.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# South Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	20.5	63.5	(33.8-108.7)	Male	10	12.7	78.8	(37.7-144.9)
Female	11	8.3	132.1	(65.8-236.3)	Female	11	10.6	104.0	(51.8-186.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.5	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
Female	3	3.7	nc	(nc-nc)	Female	3	3.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	7	11.2	62.4	(25.0-128.6)
Female	91	85.0	107.1	(86.2-131.5)	Female	13	11.0	118.6	(63.1-202.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	2.6	nc	(nc-nc)	Male	5	9.1	54.9	(17.7-128.2)
<b><u>Colon / Rectum</u></b>					Female	1	4.8	nc	(nc-nc)
Male	17	20.6	82.6	(48.1-132.3)	<b><u>Ovary</u></b>				
Female	32	23.1	138.5	(94.8-195.6)	Female	8	7.5	106.6	(45.9-210.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	5.0	nc	(nc-nc)	Male	2	7.5	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	11	8.7	126.9	(63.2-227.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	50	59.2	84.5	(62.7-111.4)
Female	0	1.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	4.7	nc	(nc-nc)
Male	8	11.1	72.3	(31.1-142.4)	Female	0	3.2	nc	(nc-nc)
Female	6	7.0	85.3	(31.2-185.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.3	nc	(nc-nc)
Male	4	2.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	3	4.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	16	14.5	110.3	(63.0-179.1)
Male	7	7.8	89.6	(35.9-184.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	6.6	122.1	(52.6-240.6)	Female	27	19.4	139.0	(91.6-202.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	7.0	nc	(nc-nc)	Male	194	251.3	77.2	(66.7-88.9)
Female	0	2.7	nc	(nc-nc)	Female	304	294.1	103.4	(92.1-115.7)
<b><u>Lung and Bronchus</u></b>									
Male	25	35.3	70.8	(45.8-104.5)					
Female	36	43.1	83.5	(58.5-115.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Southampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	8.7	80.8	(32.4-166.6)	Male	1	5.2	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	Female	1	3.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	2	4.7	nc	(nc-nc)
Female	30	30.3	99.0	(66.8-141.3)	Female	3	3.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.6	nc	(nc-nc)
Male	9	8.7	103.4	(47.2-196.3)	<b><u>Ovary</u></b>				
Female	7	6.6	105.4	(42.2-217.2)	Female	1	2.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	2.2	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.5	nc	(nc-nc)	Male	21	25.8	81.5	(50.4-124.6)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	2.0	nc	(nc-nc)
Male	2	4.6	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	4	2.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.8	nc	(nc-nc)
Male	3	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	5.5	nc	(nc-nc)
Male	1	3.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.9	nc	(nc-nc)	Female	9	7.2	124.4	(56.8-236.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	2.9	171.7	(55.3-400.7)	Male	83	106.0	78.3	(62.3-97.0)
Female	1	0.8	nc	(nc-nc)	Female	86	96.7	88.9	(71.1-109.8)
<b><u>Lung and Bronchus</u></b>									
Male	10	14.7	68.1	(32.6-125.3)					
Female	13	13.4	97.2	(51.7-166.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Southborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	9.9	70.4	(28.2-145.0)	Male	8	6.9	116.6	(50.2-229.7)
Female	6	3.5	172.7	(63.1-376.0)	Female	4	5.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.1	nc	(nc-nc)	Male	4	2.2	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	2	6.0	nc	(nc-nc)
Female	50	43.4	115.3	(85.5-152.0)	Female	4	4.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.5	nc	(nc-nc)	Male	3	5.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	2.2	nc	(nc-nc)
Male	7	11.3	62.1	(24.9-128.0)	<b><u>Ovary</u></b>				
Female	7	10.4	67.6	(27.1-139.2)	Female	1	3.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.7	nc	(nc-nc)	Male	1	3.9	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	3	3.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	0.8	nc	(nc-nc)	Male	27	33.1	81.7	(53.8-118.8)
Female	1	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.5	nc	(nc-nc)
Male	7	6.5	107.6	(43.1-221.7)	Female	1	1.4	nc	(nc-nc)
Female	2	3.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.4	nc	(nc-nc)
Male	3	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	8.4	106.9	(48.8-202.9)
Male	4	4.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	2.9	nc	(nc-nc)	Female	7	9.5	73.8	(29.6-152.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	3.9	nc	(nc-nc)	Male	118	136.1	86.7	(71.8-103.8)
Female	1	1.2	nc	(nc-nc)	Female	126	139.7	90.2	(75.1-107.4)
<b><u>Lung and Bronchus</u></b>									
Male	12	17.9	67.2	(34.7-117.3)					
Female	13	18.8	69.2	(36.8-118.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Southbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	17.5	74.2	(39.5-126.9)	Male	11	11.0	99.7	(49.7-178.5)
Female	7	7.2	96.9	(38.8-199.7)	Female	3	9.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.3	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)	Female	6	3.3	180.8	(66.0-393.4)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	13	9.9	131.9	(70.2-225.5)
Female	57	76.8	74.2	(56.2-96.1)	Female	12	9.7	123.7	(63.8-216.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.5	nc	(nc-nc)	Male	8	7.9	101.9	(43.9-200.8)
<b><u>Colon / Rectum</u></b>					Female	0	4.3	nc	(nc-nc)
Male	18	18.1	99.5	(58.9-157.3)	<b><u>Ovary</u></b>				
Female	21	20.5	102.2	(63.2-156.2)	Female	14	6.7	209.8	(114.6-352.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	4.2	nc	(nc-nc)	Male	6	6.3	94.5	(34.5-205.7)
Female	0	1.4	nc	(nc-nc)	Female	1	7.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	50	48.5	103.0	(76.5-135.9)
Female	4	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	8	4.0	198.2	(85.3-390.5)
Male	10	9.6	104.0	(49.8-191.2)	Female	3	2.9	nc	(nc-nc)
Female	8	6.2	128.8	(55.4-253.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.5	nc	(nc-nc)
Male	7	2.4	288.2	(115.4-593.8)	<b><u>Thyroid</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	2	4.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	13	13.8	94.3	(50.1-161.2)
Male	9	7.1	126.5	(57.7-240.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	5.8	171.9	(82.3-316.2)	Female	22	17.5	125.8	(78.8-190.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	5.9	136.2	(58.6-268.4)	Male	240	215.9	111.2	(97.6-126.2)
Female	2	2.4	nc	(nc-nc)	Female	241	262.3	91.9	(80.6-104.2)
<b><u>Lung and Bronchus</u></b>									
Male	45	29.7	151.7	(110.6-202.9)					
Female	31	36.9	84.0	(57.1-119.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Southwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	12.7	70.6	(32.2-134.0)	Male	5	7.8	64.1	(20.7-149.7)
Female	4	4.3	nc	(nc-nc)	Female	3	5.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.2	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	0	2.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	3	6.9	nc	(nc-nc)
Female	44	45.6	96.5	(70.1-129.6)	Female	4	5.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.5	nc	(nc-nc)	Male	6	5.5	109.4	(39.9-238.1)
<b><u>Colon / Rectum</u></b>					Female	1	2.5	nc	(nc-nc)
Male	11	13.1	83.9	(41.8-150.1)	<b><u>Ovary</u></b>				
Female	14	12.5	112.1	(61.3-188.2)	Female	4	3.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	3.0	nc	(nc-nc)	Male	2	4.5	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	2	4.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	29	34.4	84.3	(56.4-121.0)
Female	1	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.9	nc	(nc-nc)
Male	8	6.7	119.1	(51.3-234.7)	Female	2	1.8	nc	(nc-nc)
Female	7	3.7	191.2	(76.6-393.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.5	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	8.1	61.7	(19.9-144.0)
Male	2	4.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	3.5	173.6	(63.4-377.9)	Female	9	9.8	91.6	(41.8-173.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	4.1	nc	(nc-nc)	Male	120	152.6	78.7	(65.2-94.0)
Female	3	1.4	nc	(nc-nc)	Female	133	155.1	85.8	(71.8-101.6)
<b><u>Lung and Bronchus</u></b>									
Male	18	21.1	85.3	(50.5-134.8)					
Female	16	21.8	73.4	(41.9-119.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Spencer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	19	13.1	145.1	(87.3-226.6)	Male	14	8.6	162.3	(88.6-272.3)
Female	10	4.4	226.3	(108.4-416.3)	Female	8	6.4	124.5	(53.6-245.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.6	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	6	2.1	282.6	(103.2-615.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	7	7.6	91.9	(36.8-189.4)
Female	42	52.9	79.4	(57.2-107.4)	Female	7	6.3	111.9	(44.8-230.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.7	nc	(nc-nc)	Male	9	6.7	135.1	(61.7-256.6)
<b><u>Colon / Rectum</u></b>					Female	2	2.8	nc	(nc-nc)
Male	9	13.7	65.8	(30.0-124.9)	<b><u>Ovary</u></b>				
Female	12	12.4	96.6	(49.9-168.7)	Female	2	4.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	3.5	nc	(nc-nc)	Male	4	5.0	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	5	4.6	109.3	(35.2-255.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	36	43.8	82.1	(57.5-113.7)
Female	2	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	3.1	nc	(nc-nc)
Male	10	8.0	125.0	(59.8-229.9)	Female	2	1.8	nc	(nc-nc)
Female	6	4.2	144.2	(52.7-314.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.9	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	5	3.6	139.9	(45.1-326.5)
<b><u>Leukemia</u></b>					Female	10	9.9	101.4	(48.5-186.5)
Male	10	5.4	186.4	(89.2-342.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	3.7	135.7	(43.7-316.8)	Female	15	12.3	122.0	(68.2-201.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	5.0	99.5	(32.1-232.1)	Male	191	174.9	109.2	(94.3-125.9)
Female	1	1.5	nc	(nc-nc)	Female	189	173.0	109.3	(94.2-126.0)
<b><u>Lung and Bronchus</u></b>									
Male	32	23.8	134.7	(92.1-190.2)					
Female	35	23.8	147.1	(102.4-204.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	94	124.8	75.3	(60.9-92.2)	Male	27	82.8	32.6	(21.5-47.5)
Female	36	48.7	73.9	(51.7-102.3)	Female	26	73.5	35.4	(23.1-51.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	26	27.1	95.8	(62.6-140.4)	Male	22	26.5	83.1	(52.1-125.9)
Female	22	25.3	87.1	(54.5-131.8)	Female	30	23.2	129.5	(87.3-184.8)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	4	4.5	nc	(nc-nc)	Male	73	74.0	98.6	(77.3-124.0)
Female	526	586.6	89.7	(82.2-97.7)	Female	74	69.6	106.3	(83.4-133.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	37	20.2	183.6	(129.2-253.0)	Male	73	62.7	116.4	(91.2-146.3)
<b><u>Colon / Rectum</u></b>					Female	21	31.1	67.5	(41.8-103.2)
Male	149	134.5	110.8	(93.7-130.0)	<b><u>Ovary</u></b>				
Female	156	142.6	109.4	(92.9-128.0)	Female	41	50.2	81.6	(58.6-110.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	30	32.5	92.4	(62.3-131.9)	Male	48	46.9	102.4	(75.5-135.7)
Female	8	9.6	83.0	(35.7-163.5)	Female	49	50.7	96.6	(71.5-127.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	12	11.3	105.9	(54.7-185.0)	Male	310	385.0	80.5	(71.8-90.0)
Female	14	10.6	131.7	(71.9-220.9)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	38	29.9	127.3	(90.1-174.7)
Male	92	76.1	120.9	(97.5-148.3)	Female	20	20.1	99.6	(60.8-153.8)
Female	51	46.1	110.7	(82.4-145.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	12	21.6	55.6	(28.7-97.1)
Male	19	18.8	100.8	(60.7-157.4)	<b><u>Thyroid</u></b>				
Female	9	6.3	143.8	(65.6-273.0)	Male	15	36.1	41.6	(23.3-68.6)
<b><u>Leukemia</u></b>					Female	79	117.6	67.2	(53.2-83.7)
Male	47	54.2	86.7	(63.7-115.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	36	42.5	84.6	(59.3-117.1)	Female	125	131.2	95.3	(79.3-113.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	59	45.5	129.7	(98.7-167.3)	Male	1524	1645.7	92.6	(88.0-97.4)
Female	17	16.7	101.6	(59.2-162.7)	Female	1786	1931.8	92.5	(88.2-96.8)
<b><u>Lung and Bronchus</u></b>									
Male	244	219.8	111.0	(97.5-125.9)					
Female	247	258.2	95.7	(84.1-108.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sterling

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	7.0	170.9	(88.2-298.6)	Male	6	4.8	124.4	(45.4-270.8)
Female	3	3.0	nc	(nc-nc)	Female	3	4.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.5	nc	(nc-nc)	Male	4	1.5	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	7	4.3	162.9	(65.3-335.7)
Female	45	37.1	121.2	(88.4-162.2)	Female	1	4.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.3	nc	(nc-nc)	Male	1	4.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	4	1.9	nc	(nc-nc)
Male	7	8.2	85.9	(34.4-177.0)	<b><u>Ovary</u></b>				
Female	3	9.2	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	5	3.2	153.9	(49.6-359.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	38	25.0	152.0	(107.5-208.6)
Female	2	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.7	nc	(nc-nc)
Male	10	4.8	209.5	(100.3-385.4)	Female	1	1.3	nc	(nc-nc)
Female	5	2.9	175.2	(56.5-408.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.1	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	7.3	110.1	(47.4-216.9)
Male	6	3.0	197.1	(72.0-429.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.6	nc	(nc-nc)	Female	8	8.1	98.9	(42.6-194.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	2.8	nc	(nc-nc)	Male	126	98.6	127.8	(106.5-152.2)
Female	0	1.0	nc	(nc-nc)	Female	119	120.8	98.5	(81.6-117.9)
<b><u>Lung and Bronchus</u></b>									
Male	10	12.6	79.1	(37.9-145.4)					
Female	17	15.8	107.8	(62.7-172.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	3.7	nc	(nc-nc)	Male	6	2.2	268.2	(97.9-583.8)
Female	0	1.4	nc	(nc-nc)	Female	5	1.6	305.3	(98.4-712.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	11	13.6	80.8	(40.3-144.5)	Female	4	1.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.8	nc	(nc-nc)
Male	5	3.6	137.7	(44.4-321.4)	<b><u>Ovary</u></b>				
Female	6	3.8	157.9	(57.7-343.8)	Female	2	1.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	10	9.9	100.6	(48.2-185.0)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.8	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.9	nc	(nc-nc)
Male	3	1.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.0	nc	(nc-nc)	Female	6	3.2	187.1	(68.3-407.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	43	43.6	98.6	(71.3-132.8)
Female	0	0.4	nc	(nc-nc)	Female	51	48.0	106.3	(79.1-139.8)
<b><u>Lung and Bronchus</u></b>									
Male	1	6.5	nc	(nc-nc)					
Female	4	7.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Stoneham

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	32	30.0	106.5	(72.8-150.3)	Male	11	18.0	61.0	(30.4-109.2)
Female	10	9.9	100.6	(48.1-184.9)	Female	13	13.5	96.2	(51.2-164.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	4.9	141.6	(56.7-291.8)	Male	9	5.8	154.9	(70.7-294.1)
Female	5	4.3	115.0	(37.1-268.3)	Female	9	4.6	194.1	(88.6-368.4)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	12	15.9	75.6	(39.0-132.1)
Female	125	108.7	115.0	(95.7-137.0)	Female	13	13.5	96.2	(51.2-164.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	3.4	nc	(nc-nc)	Male	19	12.5	152.1	(91.5-237.5)
<b><u>Colon / Rectum</u></b>					Female	8	6.0	132.9	(57.2-261.9)
Male	32	29.7	107.8	(73.7-152.1)	<b><u>Ovary</u></b>				
Female	28	28.2	99.2	(65.9-143.4)	Female	14	9.5	147.6	(80.6-247.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	7.1	nc	(nc-nc)	Male	8	10.6	75.4	(32.5-148.6)
Female	1	1.9	nc	(nc-nc)	Female	15	10.4	144.5	(80.8-238.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	1.8	nc	(nc-nc)	Male	55	81.8	67.2	(50.6-87.5)
Female	0	1.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	10	6.8	148.1	(70.9-272.5)
Male	10	15.4	64.9	(31.1-119.3)	Female	5	4.0	125.4	(40.4-292.7)
Female	12	8.8	136.8	(70.6-239.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	3.2	156.1	(50.3-364.3)
Male	5	4.0	124.5	(40.1-290.4)	<b><u>Thyroid</u></b>				
Female	4	1.3	nc	(nc-nc)	Male	6	6.3	94.6	(34.5-205.9)
<b><u>Leukemia</u></b>					Female	30	19.4	154.8	(104.4-221.0)
Male	13	11.3	115.2	(61.3-197.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	7.9	113.4	(51.7-215.2)	Female	35	25.2	138.9	(96.7-193.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	9	9.5	94.5	(43.1-179.3)	Male	327	356.0	91.9	(82.2-102.4)
Female	8	3.3	239.4	(103.1-471.7)	Female	425	367.0	115.8	(105.1-127.4)
<b><u>Lung and Bronchus</u></b>									
Male	42	50.9	82.5	(59.5-111.6)					
Female	55	51.8	106.3	(80.0-138.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Stoughton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	33	35.7	92.4	(63.6-129.8)	Male	15	21.7	69.0	(38.6-113.9)
Female	14	12.8	109.0	(59.5-182.9)	Female	21	17.5	120.3	(74.4-183.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	6.1	81.5	(26.3-190.1)	Male	10	7.0	141.9	(67.9-261.0)
Female	6	5.6	107.1	(39.1-233.1)	Female	7	6.0	116.8	(46.8-240.7)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	13	19.3	67.3	(35.8-115.1)
Female	142	141.4	100.4	(84.6-118.4)	Female	24	17.5	137.1	(87.8-204.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	4.5	nc	(nc-nc)	Male	11	15.5	70.7	(35.3-126.6)
<b><u>Colon / Rectum</u></b>					Female	2	7.8	nc	(nc-nc)
Male	35	35.7	98.2	(68.4-136.5)	<b><u>Ovary</u></b>				
Female	42	36.4	115.5	(83.2-156.1)	Female	12	12.2	98.6	(50.9-172.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	11	8.7	126.6	(63.1-226.6)	Male	10	12.9	77.6	(37.1-142.7)
Female	3	2.5	nc	(nc-nc)	Female	17	13.5	126.0	(73.4-201.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.3	nc	(nc-nc)	Male	91	103.0	88.4	(71.2-108.5)
Female	6	2.0	297.7	(108.7-647.9)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	9	8.1	110.8	(50.5-210.3)
Male	26	18.9	137.4	(89.7-201.4)	Female	5	5.1	97.1	(31.3-226.6)
Female	16	11.3	141.2	(80.7-229.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	4.0	151.4	(55.3-329.6)
Male	9	5.0	180.9	(82.5-343.4)	<b><u>Thyroid</u></b>				
Female	3	1.6	nc	(nc-nc)	Male	10	7.9	126.4	(60.5-232.4)
<b><u>Leukemia</u></b>					Female	20	25.0	80.1	(48.9-123.7)
Male	13	13.7	94.7	(50.4-161.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	10.2	97.6	(46.7-179.5)	Female	25	32.8	76.3	(49.4-112.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	14	11.9	117.9	(64.4-197.8)	Male	428	434.6	98.5	(89.4-108.3)
Female	2	4.3	nc	(nc-nc)	Female	480	475.2	101.0	(92.2-110.5)
<b><u>Lung and Bronchus</u></b>									
Male	65	60.7	107.1	(82.7-136.5)					
Female	55	66.9	82.2	(61.9-106.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Stow

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	8.1	147.3	(76.0-257.3)	Male	5	5.2	96.0	(30.9-224.1)
Female	2	2.5	nc	(nc-nc)	Female	3	3.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.6	nc	(nc-nc)
Female	30	34.2	87.8	(59.2-125.3)	Female	4	3.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	0	4.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.7	nc	(nc-nc)
Male	14	8.8	159.0	(86.8-266.7)	<b><u>Ovary</u></b>				
Female	9	7.3	123.7	(56.5-234.9)	Female	5	2.8	178.0	(57.3-415.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.1	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	22	25.3	86.8	(54.4-131.4)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.9	nc	(nc-nc)
Male	5	4.8	103.4	(33.3-241.3)	Female	1	1.0	nc	(nc-nc)
Female	1	2.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.0	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	4	2.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	6.4	125.9	(54.2-248.1)
Male	2	3.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.1	nc	(nc-nc)	Female	8	7.9	101.0	(43.5-199.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.9	nc	(nc-nc)	Male	98	104.6	93.7	(76.0-114.2)
Female	0	0.9	nc	(nc-nc)	Female	101	106.4	94.9	(77.3-115.3)
<b><u>Lung and Bronchus</u></b>									
Male	8	13.9	57.7	(24.8-113.6)					
Female	8	14.2	56.4	(24.3-111.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sturbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	9.9	131.2	(69.8-224.4)	Male	8	6.6	121.4	(52.3-239.1)
Female	5	3.7	135.9	(43.8-317.1)	Female	8	5.3	149.7	(64.5-295.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	5	2.1	238.0	(76.7-555.5)
Female	2	1.7	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	7	5.8	120.8	(48.4-249.0)
Female	35	43.6	80.3	(55.9-111.6)	Female	3	5.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.5	nc	(nc-nc)	Male	4	5.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	2.3	nc	(nc-nc)
Male	9	10.8	83.7	(38.2-158.9)	<b><u>Ovary</u></b>				
Female	11	10.8	101.7	(50.7-181.9)	Female	1	3.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	2.6	229.3	(83.7-499.1)	Male	6	3.8	159.0	(58.0-346.0)
Female	0	0.7	nc	(nc-nc)	Female	8	3.9	204.5	(88.1-403.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	0.7	nc	(nc-nc)	Male	28	32.1	87.4	(58.0-126.3)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.4	nc	(nc-nc)
Male	7	6.1	114.4	(45.8-235.7)	Female	0	1.5	nc	(nc-nc)
Female	3	3.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.4	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	0	2.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	8.4	83.2	(33.3-171.3)
Male	5	4.1	122.8	(39.6-286.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	3.1	nc	(nc-nc)	Female	17	9.7	175.6	(102.2-281.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	3.8	nc	(nc-nc)	Male	142	131.6	107.9	(90.9-127.2)
Female	1	1.2	nc	(nc-nc)	Female	133	143.3	92.8	(77.7-110.0)
<b><u>Lung and Bronchus</u></b>									
Male	24	17.6	136.0	(87.1-202.3)					
Female	11	19.4	56.7	(28.3-101.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Sudbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	19.8	65.6	(34.9-112.2)	Male	19	13.3	142.8	(85.9-223.0)
Female	1	6.4	nc	(nc-nc)	Female	11	10.0	110.2	(54.9-197.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	4.0	176.6	(70.8-363.9)	Male	4	4.3	nc	(nc-nc)
Female	5	3.2	154.9	(49.9-361.5)	Female	3	3.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	6	11.7	51.2	(18.7-111.5)
Female	114	83.9	135.9	(112.1-163.2)	Female	12	9.5	126.8	(65.4-221.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.9	nc	(nc-nc)	Male	3	10.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	5	4.3	117.0	(37.7-273.0)
Male	24	21.9	109.5	(70.1-163.0)	<b><u>Ovary</u></b>				
Female	14	19.3	72.6	(39.6-121.7)	Female	7	7.0	100.6	(40.3-207.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	5.3	nc	(nc-nc)	Male	10	7.7	130.5	(62.5-239.9)
Female	2	1.3	nc	(nc-nc)	Female	5	6.6	75.3	(24.3-175.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	68	66.5	102.3	(79.4-129.7)
Female	2	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	4.8	nc	(nc-nc)
Male	12	12.7	94.4	(48.7-164.8)	Female	3	2.7	nc	(nc-nc)
Female	8	6.4	125.9	(54.2-248.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.4	nc	(nc-nc)
Male	2	3.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	7	5.7	123.7	(49.6-254.8)
<b><u>Leukemia</u></b>					Female	18	16.1	111.7	(66.2-176.6)
Male	7	8.2	85.8	(34.4-176.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	5.4	92.6	(29.8-216.0)	Female	16	18.7	85.4	(48.8-138.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	7.6	65.6	(21.1-153.1)	Male	226	267.6	84.5	(73.8-96.2)
Female	0	2.3	nc	(nc-nc)	Female	285	265.3	107.4	(95.3-120.6)
<b><u>Lung and Bronchus</u></b>									
Male	14	35.8	39.1	(21.4-65.7)					
Female	26	34.5	75.3	(49.2-110.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sunderland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.6	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	17	9.9	171.3	(99.7-274.3)	Female	0	1.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.6	nc	(nc-nc)
Male	1	2.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	3	2.6	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	9	8.8	102.7	(46.8-194.9)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.6	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.6	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	2.1	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.8	nc	(nc-nc)	Female	5	2.2	227.3	(73.2-530.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	29	36.0	80.6	(54.0-115.8)
Female	0	0.3	nc	(nc-nc)	Female	37	34.2	108.1	(76.1-149.1)
<b><u>Lung and Bronchus</u></b>									
Male	4	4.4	nc	(nc-nc)					
Female	2	4.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sutton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	10.9	101.3	(50.5-181.3)	Male	9	6.9	129.5	(59.1-245.8)
Female	3	2.8	nc	(nc-nc)	Female	7	4.6	150.6	(60.3-310.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.0	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	9	6.2	145.7	(66.5-276.6)
Female	38	38.3	99.2	(70.2-136.1)	Female	3	4.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.4	nc	(nc-nc)	Male	2	5.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	2.0	nc	(nc-nc)
Male	3	11.5	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	10	8.6	115.9	(55.5-213.1)	Female	1	3.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.8	nc	(nc-nc)	Male	1	4.0	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	3.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	33	33.3	99.1	(68.2-139.2)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.6	nc	(nc-nc)
Male	7	6.4	109.2	(43.7-225.0)	Female	1	1.2	nc	(nc-nc)
Female	6	2.9	209.7	(76.6-456.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.3	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	6	2.8	212.9	(77.7-463.4)
<b><u>Leukemia</u></b>					Female	6	7.7	77.7	(28.4-169.1)
Male	7	4.3	162.0	(64.9-333.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	2.5	283.4	(113.5-583.9)	Female	15	8.7	172.3	(96.4-284.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	3.9	nc	(nc-nc)	Male	130	138.8	93.7	(78.3-111.2)
Female	1	1.0	nc	(nc-nc)	Female	130	120.9	107.6	(89.9-127.7)
<b><u>Lung and Bronchus</u></b>									
Male	18	18.9	95.4	(56.5-150.8)					
Female	15	15.1	99.1	(55.5-163.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Swampscott

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	27	16.8	161.0	(106.1-234.3)	Male	20	10.5	190.0	(116.0-293.5)
Female	11	6.4	172.4	(85.9-308.5)	Female	16	8.7	184.2	(105.2-299.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.0	nc	(nc-nc)	Male	0	3.4	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	Female	5	3.0	168.3	(54.2-392.8)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	17	9.3	183.0	(106.6-293.1)
Female	75	70.0	107.1	(84.2-134.3)	Female	11	8.7	126.7	(63.2-226.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.3	nc	(nc-nc)	Male	5	7.8	63.8	(20.5-148.8)
<b><u>Colon / Rectum</u></b>					Female	3	3.8	nc	(nc-nc)
Male	19	17.4	109.5	(65.9-171.0)	<b><u>Ovary</u></b>				
Female	16	18.4	87.2	(49.8-141.6)	Female	5	6.0	83.4	(26.9-194.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	4.2	nc	(nc-nc)	Male	6	6.2	97.4	(35.6-211.9)
Female	2	1.3	nc	(nc-nc)	Female	6	6.8	88.6	(32.4-192.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	62	50.7	122.3	(93.7-156.7)
Female	4	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	3.9	nc	(nc-nc)
Male	7	9.5	73.4	(29.4-151.2)	Female	3	2.6	nc	(nc-nc)
Female	4	5.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.8	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	7	4.0	173.5	(69.5-357.6)
<b><u>Leukemia</u></b>					Female	23	12.5	184.5	(116.9-276.9)
Male	6	6.6	90.3	(33.0-196.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	5.2	174.1	(79.4-330.5)	Female	24	15.9	150.8	(96.6-224.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	5.9	nc	(nc-nc)	Male	242	210.8	114.8	(100.8-130.2)
Female	2	2.1	nc	(nc-nc)	Female	273	235.7	115.8	(102.5-130.4)
<b><u>Lung and Bronchus</u></b>									
Male	27	29.1	92.9	(61.2-135.2)					
Female	31	32.7	94.9	(64.5-134.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Swansea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	23	22.4	102.5	(65.0-153.9)	Male	8	14.0	57.3	(24.7-112.9)
Female	11	7.5	146.5	(73.1-262.2)	Female	7	9.9	70.6	(28.3-145.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	3.9	154.7	(56.5-336.7)	Male	4	4.6	nc	(nc-nc)
Female	3	3.2	nc	(nc-nc)	Female	3	3.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	10	12.3	81.0	(38.8-149.0)
Female	71	82.2	86.4	(67.5-109.0)	Female	10	10.1	99.3	(47.5-182.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.5	nc	(nc-nc)	Male	4	10.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	4	4.5	nc	(nc-nc)
Male	22	22.6	97.2	(60.9-147.2)	<b><u>Ovary</u></b>				
Female	18	20.6	87.5	(51.9-138.4)	Female	7	7.0	100.3	(40.2-206.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	5.6	nc	(nc-nc)	Male	11	8.2	133.6	(66.6-239.0)
Female	0	1.5	nc	(nc-nc)	Female	7	7.7	90.4	(36.2-186.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	1.3	nc	(nc-nc)	Male	76	67.6	112.5	(88.6-140.8)
Female	1	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	5.2	nc	(nc-nc)
Male	16	12.5	128.3	(73.3-208.4)	Female	5	2.9	171.4	(55.2-399.9)
Female	7	6.6	105.8	(42.4-218.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	2.3	213.9	(68.9-499.2)
Male	2	3.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	0.9	nc	(nc-nc)	Male	6	5.2	115.6	(42.2-251.7)
<b><u>Leukemia</u></b>					Female	12	14.1	84.9	(43.8-148.3)
Male	3	8.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	5.7	106.0	(38.7-230.8)	Female	13	19.0	68.4	(36.4-117.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	7.8	90.1	(36.1-185.6)	Male	285	279.8	101.9	(90.4-114.4)
Female	2	2.4	nc	(nc-nc)	Female	243	274.9	88.4	(77.6-100.2)
<b><u>Lung and Bronchus</u></b>									
Male	42	39.3	106.7	(76.9-144.3)					
Female	37	40.5	91.4	(64.3-126.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Taunton

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	54	56.6	95.3	(71.6-124.4)	Male	28	37.5	74.6	(49.6-107.8)
Female	26	22.4	116.1	(75.8-170.1)	Female	24	31.4	76.4	(48.9-113.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	13	11.5	112.8	(60.0-192.9)	Male	8	12.1	66.1	(28.5-130.2)
Female	8	10.2	78.5	(33.8-154.8)	Female	11	10.5	105.0	(52.3-187.9)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	4	2.0	nc	(nc-nc)	Male	34	33.3	102.1	(70.7-142.7)
Female	241	250.9	96.1	(84.3-109.0)	Female	30	30.8	97.4	(65.7-139.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	9	8.3	108.0	(49.3-205.0)	Male	46	29.0	158.8	(116.2-211.8)
<b><u>Colon / Rectum</u></b>					Female	13	13.7	94.8	(50.4-162.2)
Male	65	60.7	107.1	(82.6-136.5)	<b><u>Ovary</u></b>				
Female	73	64.6	113.1	(88.6-142.1)	Female	15	21.7	69.0	(38.6-113.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	20	15.0	133.4	(81.4-206.0)	Male	13	21.5	60.5	(32.2-103.5)
Female	1	4.4	nc	(nc-nc)	Female	24	23.4	102.4	(65.6-152.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	8	4.6	174.4	(75.1-343.7)	Male	134	182.8	73.3	(61.4-86.8)
Female	4	4.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	16	13.6	117.8	(67.3-191.2)
Male	36	34.9	103.2	(72.3-142.9)	Female	10	9.1	110.5	(52.9-203.2)
Female	14	20.1	69.6	(38.0-116.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	8	8.6	92.6	(39.9-182.5)
Male	11	8.8	125.4	(62.5-224.4)	<b><u>Thyroid</u></b>				
Female	7	2.8	252.4	(101.1-520.0)	Male	19	15.9	119.5	(71.9-186.6)
<b><u>Leukemia</u></b>					Female	61	47.0	129.9	(99.3-166.8)
Male	19	23.6	80.7	(48.5-126.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	12	18.4	65.0	(33.6-113.6)	Female	58	57.1	101.6	(77.1-131.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	29	21.4	135.8	(90.9-195.0)	Male	766	752.7	101.8	(94.7-109.2)
Female	10	7.6	132.4	(63.4-243.4)	Female	834	842.6	99.0	(92.4-105.9)
<b><u>Lung and Bronchus</u></b>									
Male	135	101.4	133.1	(111.6-157.5)					
Female	123	116.5	105.6	(87.8-126.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Templeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	11.0	72.8	(31.3-143.4)	Male	5	6.8	73.1	(23.6-170.7)
Female	4	3.2	nc	(nc-nc)	Female	2	4.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	2	6.1	nc	(nc-nc)
Female	30	38.5	77.9	(52.6-111.2)	Female	3	4.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.2	nc	(nc-nc)	Male	2	5.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	2.0	nc	(nc-nc)
Male	7	11.4	61.4	(24.6-126.4)	<b><u>Ovary</u></b>				
Female	7	9.2	76.0	(30.4-156.5)	Female	4	3.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.8	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	23	34.6	66.5	(42.1-99.7)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.6	nc	(nc-nc)
Male	7	6.3	111.5	(44.7-229.8)	Female	1	1.3	nc	(nc-nc)
Female	3	3.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.2	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	6.9	87.1	(31.8-189.7)
Male	5	4.3	117.6	(37.9-274.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.6	nc	(nc-nc)	Female	10	8.9	112.3	(53.8-206.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	3.8	130.1	(41.9-303.6)	Male	105	139.3	75.4	(61.6-91.2)
Female	1	1.1	nc	(nc-nc)	Female	108	125.6	86.0	(70.5-103.8)
<b><u>Lung and Bronchus</u></b>									
Male	20	18.9	105.8	(64.6-163.5)					
Female	18	17.8	101.0	(59.8-159.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Tewksbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	36	33.3	108.1	(75.7-149.6)	Male	19	22.0	86.5	(52.0-135.0)
Female	12	12.8	93.9	(48.5-164.1)	Female	19	17.7	107.2	(64.5-167.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	6.4	124.1	(53.4-244.5)	Male	7	7.0	99.8	(40.0-205.6)
Female	7	5.8	121.6	(48.7-250.5)	Female	5	5.9	84.1	(27.1-196.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	17	19.3	88.0	(51.2-140.9)
Female	136	146.1	93.1	(78.1-110.1)	Female	21	17.6	119.4	(73.9-182.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	7	4.7	150.0	(60.1-309.0)	Male	20	16.9	118.5	(72.4-183.1)
<b><u>Colon / Rectum</u></b>					Female	9	7.8	115.2	(52.6-218.6)
Male	34	35.7	95.3	(66.0-133.2)	<b><u>Ovary</u></b>				
Female	32	36.0	88.9	(60.8-125.5)	Female	11	12.4	88.6	(44.2-158.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	13	8.7	149.8	(79.7-256.2)	Male	14	12.6	110.9	(60.6-186.0)
Female	3	2.5	nc	(nc-nc)	Female	11	13.2	83.6	(41.7-149.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	2.4	nc	(nc-nc)	Male	102	106.0	96.2	(78.5-116.8)
Female	3	2.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	8	8.0	100.4	(43.2-197.8)
Male	30	20.3	148.0	(99.8-211.2)	Female	3	5.1	nc	(nc-nc)
Female	11	11.6	94.9	(47.3-169.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	4.5	110.9	(35.7-258.9)
Male	4	5.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.6	nc	(nc-nc)	Male	11	9.1	121.5	(60.6-217.5)
<b><u>Leukemia</u></b>					Female	28	26.4	106.2	(70.6-153.5)
Male	20	13.5	148.0	(90.4-228.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	12	10.1	118.3	(61.0-206.6)	Female	30	33.3	90.2	(60.8-128.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	12	12.4	96.6	(49.9-168.8)	Male	473	437.8	108.0	(98.5-118.2)
Female	2	4.3	nc	(nc-nc)	Female	483	483.1	100.0	(91.3-109.3)
<b><u>Lung and Bronchus</u></b>									
Male	73	59.8	122.1	(95.7-153.6)					
Female	81	68.5	118.3	(93.9-147.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	3.1	192.1	(70.2-418.2)	Male	6	2.2	267.2	(97.6-581.6)
Female	1	1.3	nc	(nc-nc)	Female	7	2.0	341.5	(136.8-703.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	25	16.7	149.8	(96.9-221.2)	Female	1	1.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.6	nc	(nc-nc)	Male	4	1.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.9	nc	(nc-nc)
Male	4	3.6	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	7	3.7	188.1	(75.4-387.6)	Female	2	1.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	4	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	13	11.3	114.9	(61.1-196.5)
Female	1	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	0.8	nc	(nc-nc)
Male	0	2.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.7	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	3.4	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.1	nc	(nc-nc)	Female	3	3.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	56	45.3	123.7	(93.5-160.7)
Female	0	0.5	nc	(nc-nc)	Female	74	54.1	136.9	(107.5-171.8)
<b><u>Lung and Bronchus</u></b>									
Male	4	5.9	nc	(nc-nc)					
Female	11	7.4	148.4	(74.0-265.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Tolland

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	2.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.5	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	9	11.5	78.3	(35.7-148.7)
Female	0	0.1	nc	(nc-nc)	Female	1	8.9	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>									
Male	1	1.5	nc	(nc-nc)					
Female	1	1.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Topsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	9.6	nc	(nc-nc)	Male	5	5.9	85.3	(27.5-199.2)
Female	4	3.5	nc	(nc-nc)	Female	8	4.3	184.7	(79.5-364.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	1.6	383.2	(139.9-834.1)	Male	0	1.9	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	6	5.1	117.3	(42.8-255.3)
Female	36	35.5	101.4	(71.0-140.4)	Female	1	4.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	2.0	nc	(nc-nc)
Male	3	9.6	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	6	9.8	61.2	(22.4-133.3)	Female	4	3.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.3	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	3.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	19	28.0	67.8	(40.8-105.8)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.2	nc	(nc-nc)
Male	8	5.2	154.1	(66.3-303.6)	Female	2	1.4	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.8	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	5.7	nc	(nc-nc)
Male	1	3.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.7	nc	(nc-nc)	Female	5	7.8	64.2	(20.7-149.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	3.2	nc	(nc-nc)	Male	85	116.9	72.7	(58.1-89.9)
Female	1	1.1	nc	(nc-nc)	Female	105	121.3	86.5	(70.8-104.8)
<b><u>Lung and Bronchus</u></b>									
Male	13	16.9	76.8	(40.8-131.3)					
Female	11	17.9	61.4	(30.6-109.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Townsend

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	8.4	166.1	(90.7-278.7)	Male	3	5.9	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)	Female	8	4.5	177.1	(76.3-349.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	3	1.5	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	9	5.3	170.8	(77.9-324.3)
Female	35	37.0	94.5	(65.8-131.5)	Female	2	4.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.3	nc	(nc-nc)	Male	4	5.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	4	1.9	nc	(nc-nc)
Male	10	9.7	103.2	(49.4-189.8)	<b><u>Ovary</u></b>				
Female	17	8.2	206.8	(120.4-331.1)	Female	1	3.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	2.5	324.4	(139.7-639.2)	Male	4	3.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	23	32.3	71.1	(45.1-106.8)
Female	2	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.1	nc	(nc-nc)
Male	10	5.9	168.4	(80.6-309.7)	Female	2	1.2	nc	(nc-nc)
Female	5	2.8	177.8	(57.3-414.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.4	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	7.6	118.3	(54.0-224.6)
Male	2	3.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.4	nc	(nc-nc)	Female	3	8.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.6	nc	(nc-nc)	Male	130	122.8	105.9	(88.5-125.7)
Female	0	1.0	nc	(nc-nc)	Female	128	116.9	109.5	(91.3-130.2)
<b><u>Lung and Bronchus</u></b>									
Male	15	15.6	96.2	(53.8-158.7)					
Female	16	14.8	108.0	(61.7-175.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Truro

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	3.5	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	4	1.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	13	12.7	102.1	(54.3-174.6)	Female	1	1.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.7	nc	(nc-nc)
Male	6	3.4	175.4	(64.1-381.8)	<b><u>Ovary</u></b>				
Female	4	2.8	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	2	0.2	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	7	11.5	60.8	(24.4-125.2)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.8	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.8	nc	(nc-nc)
Male	3	1.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.8	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	1.2	nc	(nc-nc)	Male	40	43.5	91.9	(65.7-125.2)
Female	0	0.4	nc	(nc-nc)	Female	46	41.2	111.7	(81.8-149.0)
<b><u>Lung and Bronchus</u></b>									
Male	6	6.1	97.9	(35.7-213.0)					
Female	3	6.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Tyngsborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	8.9	67.3	(24.6-146.6)	Male	5	6.8	73.1	(23.6-170.6)
Female	7	3.3	215.3	(86.2-443.6)	Female	4	5.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.3	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	6	6.1	98.3	(35.9-213.9)
Female	50	46.1	108.4	(80.4-142.9)	Female	3	5.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.8	nc	(nc-nc)	Male	4	6.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	2.3	nc	(nc-nc)
Male	12	11.3	105.9	(54.7-185.1)	<b><u>Ovary</u></b>				
Female	6	10.5	57.2	(20.9-124.5)	Female	4	3.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.7	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	3.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	37	36.4	101.6	(71.5-140.0)
Female	0	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	2.4	209.8	(67.6-489.5)
Male	8	7.0	114.1	(49.1-224.8)	Female	1	1.5	nc	(nc-nc)
Female	3	3.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	2.0	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	10.1	nc	(nc-nc)
Male	6	4.1	145.1	(53.0-315.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	3.0	164.1	(52.9-383.0)	Female	11	10.1	109.2	(54.5-195.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	4.3	nc	(nc-nc)	Male	139	139.6	99.6	(83.7-117.6)
Female	2	1.2	nc	(nc-nc)	Female	140	144.5	96.9	(81.5-114.3)
<b><u>Lung and Bronchus</u></b>									
Male	22	16.8	130.7	(81.9-197.9)					
Female	22	17.1	128.3	(80.4-194.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Tyringham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	3	3.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	3.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	0.4	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	5	12.3	40.7	(13.1-94.9)
Female	1	0.1	nc	(nc-nc)	Female	7	10.9	64.5	(25.8-132.9)
<b><u>Lung and Bronchus</u></b>									
Male	1	1.9	nc	(nc-nc)					
Female	0	1.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Upton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	7.2	83.4	(30.4-181.4)	Male	4	5.1	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.6	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
Female	44	30.6	143.8	(104.5-193.0)	Female	5	3.3	153.1	(49.3-357.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.5	nc	(nc-nc)
Male	6	8.3	72.1	(26.3-156.9)	<b><u>Ovary</u></b>				
Female	3	6.5	nc	(nc-nc)	Female	5	2.6	195.4	(63.0-456.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	2.1	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	6	2.2	276.9	(101.1-602.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	26	26.4	98.4	(64.3-144.2)
Female	1	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.8	nc	(nc-nc)
Male	3	5.0	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.1	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	6.4	108.9	(43.6-224.4)
Male	3	3.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.9	nc	(nc-nc)	Female	12	6.9	174.8	(90.2-305.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	3.1	160.5	(51.7-374.6)	Male	93	103.4	90.0	(72.6-110.2)
Female	2	0.8	nc	(nc-nc)	Female	125	94.8	131.8	(109.7-157.0)
<b><u>Lung and Bronchus</u></b>									
Male	14	13.3	105.5	(57.7-177.1)					
Female	18	12.0	150.0	(88.9-237.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Uxbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	10.1	178.6	(105.8-282.3)	Male	11	7.3	150.0	(74.8-268.4)
Female	5	5.1	97.4	(31.4-227.3)	Female	4	7.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.4	nc	(nc-nc)	Male	5	2.3	213.9	(68.9-499.1)
Female	2	2.5	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	8	6.6	122.0	(52.6-240.5)
Female	64	60.5	105.8	(81.5-135.2)	Female	6	7.2	83.4	(30.5-181.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.0	nc	(nc-nc)	Male	16	6.1	261.3	(149.3-424.4)
<b><u>Colon / Rectum</u></b>					Female	3	3.2	nc	(nc-nc)
Male	17	11.9	143.0	(83.2-228.9)	<b><u>Ovary</u></b>				
Female	11	15.1	73.0	(36.4-130.6)	Female	9	5.2	173.5	(79.2-329.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.9	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	3	5.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	51	37.8	134.8	(100.4-177.2)
Female	1	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.6	nc	(nc-nc)
Male	16	7.2	221.5	(126.5-359.7)	Female	1	2.1	nc	(nc-nc)
Female	5	4.8	105.0	(33.9-245.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	2.0	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	1	3.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	11.4	79.1	(36.1-150.2)
Male	6	4.6	131.1	(47.9-285.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	4.3	116.5	(37.5-271.8)	Female	12	13.7	87.8	(45.3-153.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	4.4	112.6	(36.3-262.9)	Male	218	148.9	146.4	(127.6-167.2)
Female	2	1.8	nc	(nc-nc)	Female	188	199.2	94.4	(81.4-108.9)
<b><u>Lung and Bronchus</u></b>									
Male	26	18.8	138.3	(90.3-202.6)					
Female	28	26.9	104.1	(69.2-150.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wakefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	27	31.9	84.7	(55.8-123.3)	Male	19	20.1	94.3	(56.8-147.3)
Female	12	10.1	118.9	(61.4-207.8)	Female	22	14.6	150.3	(94.1-227.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	5.8	138.4	(59.6-272.7)	Male	4	6.5	nc	(nc-nc)
Female	6	4.7	126.6	(46.2-275.6)	Female	4	4.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	11	17.7	62.2	(31.0-111.3)
Female	127	118.5	107.2	(89.4-127.5)	Female	15	14.1	106.2	(59.4-175.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.9	nc	(nc-nc)	Male	15	14.3	105.2	(58.8-173.5)
<b><u>Colon / Rectum</u></b>					Female	7	6.4	109.5	(43.9-225.6)
Male	30	32.1	93.4	(63.0-133.3)	<b><u>Ovary</u></b>				
Female	29	29.3	99.0	(66.3-142.2)	Female	7	10.2	68.9	(27.6-142.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	7.9	113.7	(51.9-215.8)	Male	11	11.6	94.8	(47.3-169.7)
Female	0	2.0	nc	(nc-nc)	Female	10	10.6	94.8	(45.4-174.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	2.2	nc	(nc-nc)	Male	53	90.8	58.4	(43.7-76.4)
Female	1	1.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	7.4	67.8	(21.8-158.1)
Male	11	17.6	62.4	(31.1-111.6)	Female	2	4.1	nc	(nc-nc)
Female	12	9.3	128.4	(66.3-224.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	4.1	nc	(nc-nc)
Male	2	4.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.3	nc	(nc-nc)	Male	8	7.7	103.9	(44.7-204.7)
<b><u>Leukemia</u></b>					Female	21	22.6	93.1	(57.6-142.3)
Male	18	12.5	144.1	(85.3-227.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	8.3	83.9	(33.6-172.9)	Female	24	27.1	88.5	(56.7-131.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	10.8	73.9	(31.8-145.6)	Male	304	394.9	77.0	(68.6-86.1)
Female	3	3.4	nc	(nc-nc)	Female	396	391.3	101.2	(91.5-111.7)
<b><u>Lung and Bronchus</u></b>									
Male	38	56.5	67.3	(47.6-92.3)					
Female	57	53.3	107.0	(81.0-138.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wales

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	2.3	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	8	8.9	89.4	(38.5-176.2)	Female	0	1.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.5	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	7	2.0	352.1	(141.1-725.4)	Female	1	0.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	5	7.5	66.8	(21.5-155.9)
Female	1	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.6	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.7	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.6	nc	(nc-nc)	Female	5	2.2	230.5	(74.3-538.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	0.8	nc	(nc-nc)	Male	21	30.3	69.3	(42.9-106.0)
Female	1	0.2	nc	(nc-nc)	Female	30	28.4	105.7	(71.3-150.9)
<b><u>Lung and Bronchus</u></b>									
Male	3	4.1	nc	(nc-nc)					
Female	2	3.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;